Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

COGNITIVE BEHAVIOUR THERAPY and PSYCHOSOCIAL REHABILITATION vs usual care

Drug (non‐alcohol) use ‐ not measured · people with both severe mental illness and substance misuse

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for people with both severe mental illness and substance misuse 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COGNITIVE BEHAVIOUR THERAPY and PSYCHOSOCIAL REHABILITATION vs usual care

Mental state ‐ not measured · people with both severe mental illness and substance misuse

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for people with both severe mental illness and substance misuse 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COGNITIVE BEHAVIOUR THERAPY and PSYCHOSOCIAL REHABILITATION vs usual care

Global State‐ not measured · people with both severe mental illness and substance misuse

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for people with both severe mental illness and substance misuse 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COGNITIVE BEHAVIOUR THERAPY and PSYCHOSOCIAL REHABILITATION vs usual care

Quality of life/life satisfaction ‐ not measured · people with both severe mental illness and substance misuse

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for people with both severe mental illness and substance misuse 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Quality of life: respiratory domain · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1132 participants
Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 946 participants
Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 944 participants
Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 944 participants
Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1057 participants
Moderate

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 506 participants
Moderate

Specialised cognitive behavioural therapy‐based physiotherapy vs WAIT LIST

Reduction in physical signs End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

The review found no eligible studies for this question.

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Specialised cognitive behavioural therapy‐based physiotherapy vs WAIT LIST

Level of functioning · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Low